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Summary Telomerase is a ribonucleoprotein capable of replacing telomeric DNA sequences that are lost at each cell division. Under normal
circumstances, it is active in rapidly dividing embryonic cells and in stem cell populations but not in terminally differentiated somatic cells.
Much attention has recently focused on the hypothesis that activity of this enzyme is necessary for cells to become immortal. This predicts
that telomerase activity should be detectable in malignant cells and tissues but not in their normal counterparts, which slowly senesce and die.
In accordance with this notion, telomerase activity has been reported in a wide range of malignancies, including those of the gastrointestinal
tract, breast and lung. In the present study, we used a polymerase chain reaction (PCR)-based assay for telomerase activity, designated the
'telomeric repeat amplification protocol (TRAP)', to examine initially 35 colonic carcinomas, their corresponding normal tissues and 12
inflammatory bowel disease (IBD) lesions. We detected strong enzyme activity in 32 (92%) of the 35 colon carcinomas while there was no
activity in 30 (86%) of 35 matched normal colonic tissue specimens and only very weak activity in the remainder. Four of seven specimens of
ulcerative colitis and two of five Crohn's disease lesions were negative, and the rest were only weakly positive. These results led us to
examine whether telomerase could be detected in carcinoma cells exfoliated into the colonic lumen. We assayed lysates of exfoliated cells in
luminal washings from colectomy specimens of 15 patients with colon carcinoma and nine with IBD. Telomerase activity was detected in
washings from 9 (60%) of the 15 colon carcinoma cases but not in any from cases with IBD, suggesting that it can be a good marker for the
detection of colon carcinoma, possibly even in non-invasively obtained samples.
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Colorectal carcinoma is a common gastrointestinal neoplasm in
many countries. Recent advances in surgical treatment, chemo-
therapy, radiotherapy and immunotherapy have greatly improved
the prognosis of such patients. However, despite improvements in
the clinical investigation of bowel disorders, including double-
contrast barium enema and endoscopy, the early detection of
colorectal carcinoma is still a major clinical problem. These
methods are expensive, uncomfortable and labour intensive.
Conversely, the presence of fresh or occult blood in the stool is a
frequent feature in symptomatic disease and is an easy test for
screening but it is not specific for carcinoma. A reliable, prefer-
ably non-invasive, method is therefore urgently needed for evalua-
tion of symptomatic and asymptomatic individuals, especially
high-risk patients.
One approach to this problem is to identify reliable molecular
biomarkers for the detection ofcolon carcinomas, and a number of
candidates have recently been suggested. These include mutations
in tumour-suppressor genes such as p53 (Hollstein et al, 1991),
APC (Kinzler et al, 1991a), MCC (Kinzler et al, 1991b) and DCC
(Fearon et al, 1990a). Mutations in DNA mismatch repair genes
Received 23 May 1996
Revised 4 September 1996
Accepted 13 September 1996
Correspondence to: D Tarin
(Leach et al, 1993) and oncogenes such as Ki-ras (Fearon et al,
1990b; Smith-Ravin et al, 1995) have also been implicated.
More recently, the enzyme telomerase has been attracting
interest as another promising candidate marker (Counter et al,
1994). The 'telomere hypothesis' proposes that activation of
telomerase is necessary for cells to become immortal or capable of
extended proliferation (Rhyu, 1995; Shay et al, 1995). Telomeres
are specialized nucleoprotein structures at the ends of eukaryotic
chromosomes which contain multiple tandem repeats (Greider
et al, 1987; Morin, 1989). They are believed to have a role in
protecting the end ofthe chromosome from fusion and recombina-
tion events by interactions with DNA-binding proteins and with
those of the nuclear matrix. Sormatic cell telomeres are progres-
sively shortened by 40-200 bp with each cell division, and reduc-
tion beyond a critical point leads to subsequent exit from the
cell cycle and senescence (Harley et al, 1990, 1991; Counter et al,
1992; Greider, 1994). The restoration of telomeric repeats to the
ends of the chromosome may overcome this limitation, and this
maintenance function is performed by the enzyme telomerase.
Telomerase is a ribonucleoprotein that synthesizes TTAGGG
tandem repeats at each telomeric region to re-extend it to its orig-
inal length (Morin, 1989). The enzyme is active in embryonic cells
and in stem cells but activity is undetectable in normal, terminally
differentiated somatic cells (Kim et al, 1994). Cells that can over-
come this limitation have the potential for prolonged survival and
indefinite proliferation, and recent data indicate that telomerase is
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indeed reactivated in immortal cancer cells. Activation of telom-
erase in a cell may lead to the evolution of a clonal line with
enhanced survival capabilities and the potential to develop into a
tumour (Harley, 1991; Rhyu, 1995; Shay et al, 1995). Hence, ifthe
'telomere hypothesis' applies to human malignancy, one might
predict that telomerase activity would be detectable in the initial
stages of neoplasia and could therefore be a particularly useful
marker for early diagnosis.
In the present study, we assessed whether telomerase activity
could be a good diagnostic marker of colonic carcinoma. The
enzyme activity was initially assayed in colorectal carcinoma
tissues, matched adjacent normal tissues and IBD lesions.
Furthermore, to elucidate whether it would be possible to detect
cancer cells in colonic luminal washings, telomerase activity was
assayed in the lysate of exfoliated cells obtained from colonic
luminal washings of resected specimens. This study demonstrates
the feasibility ofnon-invasive colonic cancer detection by analysis
ofcolonic luminal washings or stool samples from patients.
MATERIALS AND METHODS
Procurement of tissues and exfoliated cells from
colonic washings
Surgically resected tissue samples from 35 colorectal carcinomas,
their corresponding normal counterparts and 12 IBD lesions,
including seven specimens of ulcerative colitis and five of Crohn's
disease, were snap frozen and stored in liquid nitrogen until use.The
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presence of viable carcinoma cells in tissue obtained from cancer
specimens and the suitability of normal tissues for use as controls
was routinely confirmed by cryostat sectioning before analysis.
Exfoliated cells were collected from 15 colorectal cancer speci-
mens and from nine affected by IBD. The IBD group included five
ulcerative colitis and four Crohn's disease specimens. The lumen
of each surgically resected specimen was washed with water to
remove faecal debris and then with 500 ml ofphysiological saline,
which was collected before opening the bowel for pathological
examination and tissue sampling. A 1-ml aliquot of the saline
washings was removed for cytology afterwhich the remainder was
centrifuged at 3000 r.p.m. for 15 min. The resulting cell pellets
were snap frozen in liquid nitrogen and stored at -80°C.
Protein extraction
Protein extractions from cell lines were performed according to
protocols published previously (Kim et al, 1994). The HT29
human colon carcinoma cell line was routinely cultured in RPMI
1640 medium (Gibco, BRL, Paisley, UK) supplemented with 10%
fetal calf serum at 37°C in an atmosphere containing 5% carbon
dioxide. Cells were harvested and centrifuged at 3000 r.p.m. for 5
min and the cell pellet was washed with ice-cold washing buffer
[10 mM Hepes-potassium hydroxide (pH 7.5), 1.5 mm magnesium
chloride, 10 mm potassium chloride, 1 mM dithiothreitol], pelleted
again andresuspended in fourvolumes ofthe cell pellet ofice-cold
TRAP lysis buffer [10 mM Tris-HCl (pH 7.5), 1 mm magnesium
chloride, 1 mm EGTA, 0.1 mm AEBSF (ICN Biomedicals, Thame,
UK), 5 mm P-mercaptoethanol, 0.5% CHAPS, 10% glycerol].
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Figure 1 Telomerase activity in colon carcinoma tissues and in normal colonic tissues (cases 71, 72, 73, 76). T represents tumour tissues and N represents
normal tissues. Six micrograms of tissue lysate protein was used for each reaction. Positive results consisting of intense extended 6 bp ladders were clearly
observed in tumour tissues. Normal tissues showed either no signal or occasionally a faint short ladder (e.g. case 72). The enzyme activity in the cell lysate
(6 jg of protein) was also examined in ulcerative colitis (UC) and Crohn's disease (CD) lesions. Weak enzyme activity was observed in the lysate of UC patient
cases 2 and 3 and CD patient cases 1 and 2. Cell lysate (6 9g of protein) from a HT29 human colon carcinoma cell line was used as a positive control. The
activity was not detected in a reaction mixture containing no cell lysate
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Tissues from colorectal carcinomas and from matched normal
mucosa were histologically verified by cryostat sectioning before
analysis. For protein extraction, 20 cryostat sections (10-jim thick)
from each sample, were dissolved in 50-70 ,ul of ice-cold TRAP
lysis buffer, incubated for 30 min on ice and centrifuged for 30 min
at 14 000 r.p.m. at 4°C. The supernatant was decanted, snap frozen
and stored at -80°C. The frozen pellet of exfoliated cells from
colon luminal washings were washed with washing buffer and
then dissolved in the lysis buffer of four cell-pellet volumes and
lysed in the same manner as tissues. Protein concentrations were
measured by Bio-Rad protein assay kit (Bio-Rad, UK) and were in
the range of 5-10 mg ml-'. Six micrograms of the extract were
used for each telomerase assay.
Telomerase assay
Telomerase activity was assayed by a modification of the 'telom-
eric repeat amplification protocol (TRAP)' (Kim et al, 1994).
Briefly, 2 p1 of the cell extract (3 jig protein .tl ') were incubated
with 20 mm Tris-HCI (pH 8.3), 1 mm magnesium chloride, 63 mM
potassium chloride, 0.005% Tween-20, 1 mm EGTA, 50 mM
deoxynucleotide triphosphate, 0.4 ji of [oc-32P]dCTP (10 mCi
ml-', 3000 Ci mmol-', Amersham, UK), 1 ,ug of T4g32 protein
(Boehringer Mannheim), bovine serum albumin (0.1 mg ml-'), 2
units of Taq DNA polymerase (Boehringer Mannheim) and 0.1 jig
of TS primer (5'-AATCCGTCGAGCAGAGTT-3') at 20°C for
30 min and then heated at 90°C for 3 min. During the latter step,
0.1 jig of CX primer (5'-CCCTTACCCTTACCCTTACCCT AA-
3') was added, and the reaction mixture was subjected to 31
PCR cycles of94°C for 45 s, 50°C for 45 s and 72°C for 90 s. For
assessment of the sensitivity of the telomerase assay, extracts
containing 6 jg, 0.6 jig and 0.06 jg ofprotein were routinely used
in the TRAP reaction. Confirmation of the RNAase A-sensitivity
of positive telomerase assays was performed as follows: 10 jil of
cell extract were digested with 0.5 jig of RNAase A (Boehringer)
for 20 min at 37°C. and 2 jil of the protein extract was used in the
TRAP reaction. The TRAP assay results were visualized by elec-
trophoresis of 15 jl of the PCR products in 0.5 x Tris-borate
EDTA buffer in 12% polyacrylamide non-denaturing gels. Gels
were dried and exposed to radiographic film overnight at room
temperature.
RESULTS
Telomerase activity in colorectal carcinoma tissues
In this assay, telomerase activity is recognized by a distinctive
series of bands present in an electrophoretic gel or on autoradi-
ographic film. Each band differs in size from its neighbour by the
addition ofa further TTAGGG repeat, creating the appearance ofa
6 bp ladder (Figure 1).
Telomerase activity was detected in 32 (92%) of the 35
colorectal carcinomas examined, while it was not detected in 30
(86%) ofthe 35 matched normal tissues from the same patients and
was only very weakly present in the remainder. Representative
results are shown in Figure 1. In this figure, it can be seen that,
although telomerase activity was detected in all the tumour samples
shown, the intensity of the signal differed from case to case. An
example of a weakly positive normal tissue sample is also shown
(case 72). In order to compare the intensity ofthe activity present in
the different samples, cell lysates were serially diluted before the
Table 1 Telomerase activity of colon carcinoma tissues
Telomerase activity
Undetectable (n = 3) Detectable (n = 32)
Age at diagnosis (year) 66-76 47-85
Mean age atdiagnosis 72 68
Sex (male-female) 0: 3 21:11
Tumour stage (Dukes)
A 0 4
B 0 16
C 2 12
D 1 0
Histologya
Well 0 4
Mod. 2 24
Poor, Muc., Signet 1 4
[32/35 (92%)]
aWell, well-differentiated adenocarcinoma; Mod, moderately differentiated
adenocarcinoma; Poor, poorly differentiated adenocarcinoma; Muc,
mucinous carcinoma; Signet, signet ring cell carcinoma.
lq cn) C0l
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Figure 2 Telomerase activity in exfoliated cell lysates from colon luminal
washings of cancer patients (cases 24, 29 and 32). Telomerase activity was
detected in cell lysates (6 9g of protein) from cancer patients, and its activity
was not detected in the RNAase A-pretreated cell lysates
TRAP assay was performed. Telomerase activity could not be
detected in normal tissue lysates which were diluted 100-fold (0.06
jig). However, it was detected in 60% of colon carcinoma tissue
lysates, even after 100-fold dilution (0.06 jig). The clinicopatho-
logical details of each of the carcinoma cases are compared with
the corresponding observed activity of the enzyme in Table 1.
There was no correlation between telomerase activity and tumour
stage. The enzyme activity was also measured in IBD lesions
(Figure 1). Although it was very much weaker in these lesions than
in carcinomas, activity was detected in three ofseven specimens of
ulcerative colitis and three offive specimens ofCrohn's disease.
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Table 2 Clinicopathological details of colorectal carcinoma cases
Case number Age (years) Sex Locationa Histologyb T N Dukes' stage Cytology FOB Telomerase
4 54 M A Muc. 2 2 C - + +
24 47 F R Well 3 1 C SUS + +
26 73 M R Poor 4 2 C - ND
27 59 F S Mod. 3 1 C + + +
28 59 F R Mod. 3 1 C - + +
29 72 M C Mod. 3 2 C ND + +
30 68 M R Mod. 4 0 B SUS ND +
32 75 M A Mod. 3 0 B - ND +
34 67 F R Mod. 3 0 B + + +
35 65 F R Mod. 3 1 C - + -
36 56 M R Poor 4 2 C - ND
37 60 M C Muc. 3 0 B - ND -
38 77 F A Mod. 3 0 B - - -
39 82 M A Mod. 3 1 C SUS + +
40 83 M S Mod. 3 0 B ND - -
aA, ascending colon; S, sigmoid colon; C, caecum; R, rectum. bHistology; T and N were followed according to UICC classification. Well, well-differentiated
adenocarcinoma; mod, moderately differentiated adenocarcinoma; poor, poorly differentiated adenocarcinoma; muc, mucinous carcinoma. ND, not done; SUS,
suspicious; FOB, faecal occult blood.
Table 3 Validity of telomerase assays on colonic washings from a hospital-
based patient population
Carcinoma
Telomerase result Present Absent Total
Positive 9 (a) 0 (b) 9 (a + b)
Negative 6 (c) 9 (d) 15 (c + d)
Total 15 (a + c) 9 (b + d) 24 (n)
Sensitivity a/(a + c) = 60%; specificity d/(d + b) = 100%; positive predictive
value a/(a + b) = 100%.
Telomerase activity in exfoliated cancer cells in colonic
luminal washings
The prevalence of telomerase activity in solid tumour tissues
described above suggested that the assay could be a useful marker
for the detection of cancer cells shed into body fluids. To evaluate
the possibility that tumour cells might be detectable in stool speci-
mens by their level of telomerase activity, we assayed luminal
washings collected from the resected specimens of 15 colon
cancer patients and nine with IBD, resected at the time of surgery.
In order to determine the sensitivity of the assay, cells from a
cultured tumour cell line were serially diluted in culture medium,
lysed and the resulting protein extracts were assayed for the pres-
ence oftelomerase activity. As we have recently described (Sugino
et al, 1996), telomerase activity was detected in extracts from a
total ofonly four cancer cells (data not shown).
Telomerase activity, visualized on an autoradiograph as a ladder
of PCR products, was detectable in lysates of exfoliated cells
obtained from cancer patients (Figure 2). Positive signals were
always abrogated by preincubation of a known positive extract
with RNAase A. This indicates that the signals were attributable to
telomerase, as the active site ofthe enzyme contains a ribonucleic
acid moiety and is therefore destroyed by this treatment. The posi-
tive signals previously observed in cases 24,29 and 32 were abol-
ished by RNAase A digestion, indicating the specificity of the
assay for telomerase.
Extracts from 9 (60%) of 15 colon luminal washings from colon
cancer patients exhibited telomerase activity with varying signal
intensities. Enzyme activity was not detected in cell lysates from
IBD patients. The clinicopathological data, including the cytolog-
ical and faecal occult blood results ofthe patients, are presented in
Table 2, and the specificity, sensitivity and positive predictive
values ofthis assay are analysed in Table 3.
DISCUSSION
Following the development by Kim et al (1994) of an extremely
sensitive PCR-based assay, telomerase activity has been found in a
large variety of solid tumours, including neuroblastomas (Hiyama
et al, 1995a), lung carcinomas (Hiyama et al, 1995b), hepatomas
(Tahara et al, 1995a), gastric and colon carcinomas (Chadeneau et
al, 1995; Hiyama et al, 1995c; Tahara et al, 1995b Li et al, 1996),
breast carcinomas (Hiyama et al, 1996; Sugino et al, 1996) and
brain tumours (Langford et al, 1995). In the present study, the
activity of this enzyme was demonstrated in more than 90% of
colorectal carcinomas in line with previous studies (Chadeneau et
al, 1995; Tahara et al, 1995b; Li et al, 1996). However, it was also
detected, although weakly, in IBD lesions and in 14% of normal
mucosal specimens. Some of our weakly positive results in a small
proportion of normal mucosal specimens and in IBD might be
attributable to the replicative activity of stem cells in the basal
portion of the crypts, as is the case in the cells of the testis and
ovary. Infiltrating lymphocytes may also contribute to the positive
assays in IBD lesions as the activity of this enzyme can also be
detected in peripheral blood lymphocytes (Hiyama et al, 1995d).
However,the level oftelomerase activity thatwe detected in tumour
tissues was far strongerthan in IBD and normal colon tissues. Thus,
enzyme activity was notdetected in 100-fold diluted lysate (0.06,g
of protein) from IBD lesions nor in normal tissues while it was
detected in 60% of the 100-fold diluted lysate (0.06 jg ofprotein)
obtained from colorectal carcinoma tissues. It is not yet known
whether the intensities of the signals correlate with the number of
immortal cells present or whether some immortal cells possess
more activity than others. In this study, the presence of telomerase
activity in colon tissue samples did not correlate with either the
Dukes' tumour stage or the histological type ofthe tumours.
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In a similar study, Tahara et al (I995b) demonstrated that telom-
erase activity could be detected in 95% of 20 colonic cancer spec-
imens but not in any of the corresponding normal tissues. Activity
was also detected in all of the colonic adenomas they examined,
suggesting that the enzyme might be activated in the early stages
ofcarcinogenesis or that it becomes detectable in circumstances in
which there is extensive glandular regeneration or reduplication.
The above results seemed to indicate that telomerase activity
could be a useful ancillary tool for colorectal cancer diagnosis, and
this led us to examine the feasibility of detecting exfoliated carci-
noma cells in colonic luminal washings using this method. It was
reasoned that the TRAP assay is so sensitive that, even ifthe exfo-
liated carcinoma cells in the washings are only a minority subpop-
ulation among many normal surface epithelial and inflammatory
cells, it could still provide a powerful method for their detection.
I'his possibility is ofclinical interest because it could be beneficial
to be able to detect dissociated cancer cells in clinical specimens
obtained non-invasively or, at least, minimally invasively.
We have previously shown that elevated quantities of unusual
CD44 transcripts and protein isoforms are detectable in exfoliated
cells present in naturally micturated urine from bladder cancer
patients (Matsumura et al, 1994). Moreover, exfoliated carcinoma
cells in colon luminal washings were also shown to be detectable
in about 73% ofcases, when using CD44 exons 11 and 12 as detec-
tion markers (Yoshida et al, 1996). The present data, obtained by
assay oftelomerase activity has again demonstrated the possibility
ofdetecting exfoliated carcinoma cells in tumour-bearing samples.
Analysis of the data obtained in this study (Table 3) gives encour-
aging values for the sensitivity and specificity of cancer detection
and for the positive predictive value of the method. Moreover, the
washings from all cases ofinflammatory bowel disease were nega-
tive for telomerase activity, indicating that any inflammatory cells
which might have been harvested in the washings, did not produce
enough signal to compromise the specificity of cancer cell detec-
tion. The clinical implication of such results is that the application
of these techniques to evacuated stool specimens might result in a
new non-invasive test for colorectal cancer. Clinical bowel prepa-
ration regimens which render the stools liquid and evacuate the
lumen in preparation for surgery or radiological and endoscopic
examination may be helpful for this purpose.
The proportion of colorectal cancer patients in whom we have
identified telomerase activity in the colonic luminal contents and,
thus, inferred the presence of exfoliated cancer cells compares
favourably with data published in previous reports, using other
molecular markers. For example, Ki-ras mutations were found in
DNA retrieved from 50% of stool samples from 11 colorectal
carcinoma cases (Smith-Ravin et al, 1995). However, the encour-
aging results in our present report could be attributable partly to
the mode of obtaining the exfoliated cells, i.e. by the washing out
ofexcised colons, or possibly to the relative simplicity of the tech-
niques for the detection of telomerase activity. Even so, the results
suggest that telomerase can be a promising candidate marker for
cancer diagnosis and provide the incentive for further analytical
work on the difficult topic of defaecated stool analysis.
The molecular analysis of colonic luminal washings could also
be a useful adjunct to endoscopy in establishing the diagnosis of
colorectal cancer. We are now evaluating this by conducting
studies on exfoliated cells obtained by washing of the colon during
bowel preparation before radiological examination or surgery. In
some cases, it proves difficult to examine the entire lumen of the
colon internally and, in others, there is uncertainty about whether a
stricture results from carcinoma, IBD ordiverticulitis. Examination
of exfoliated cells present in the luminal washings in such cases
might help make a diagnosis.
The findings described above therefore indicate that telomerase
may make a useful contribution to colorectal cancer diagnosis.
ACKNOWLEDGEMENTS
We thank Mrs Linda Summerville for preparation of the manu-
script, Miss Helene Mellor for photography and Mrs Susannah
Crowley and Miss Heather Dorricott for their technical assistance.
REFERENCES
Chadeneau C. Hay K, Hirte HW, Gallinger S and Bacchetti S (1995) Telomerase
activity associated with acquisition of malignancy in human colorectal cancer.
Cancer Res 55: 2533-2536
Counter CM, Avilion AA, Lefeuvre CE, Atewart NG, Greider CW, Harley CB and
Bacchetti S (1992) Telomere shortening associated with chromosome
instability is arrested in immortal cells which express telomerase activity.
EMBO J 11: 1921-9
Counter CM, Hirte HW, Bacchetti S and Harley CB (1994) Telomerase activity in
human ovarian carcinoma. Proc Natl Acad Sci USA 91: 2900-2904
Fearon ER, Cho KR, Nigro JM, Kem SE, Simons JW, Ruppert JM, Hamilton SR,
Preisinger AC, Thomas G, Kinzler K and Vogelstein B (I990a) Identification
of a chromosome 1 8q gene that is altered in colorectal cancers. Scienice 247:
49-56
Fearon ER and Vogelstein B (1990b) A genetic model for colorectal tumorigenesis.
Cell 61: 759-767
Greider CW (1994) Mammalian telomere dynamics: healing, fragmentation,
shortening and stabilization. Current Opin Getnet Des,el 4: 203-21 1
Greider CW and Blackburn EH (1987) The telomere terminal transferase of
Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer
specificity. Cell 51: 887-98
Harley CB (1991) Telomere loss: mitotic clock or genetic time bomb? Mutationl Res
256: 271-282
Harley CB, Futcher AB and Greider CW (1990) Telomeres shorten during ageing of
human fibroblasts. Nature 345: 458-460
Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA and Shay JW
(1995a) Correlating telomerase activity levels with human neuroblastoma
outcome. Nature Med 1: 249-255
Hiyama K, Hiyama E, Ishioka S, Yamakido M, Inai K, Gazdar AF, Piatyszek MA
and Shay JW (1995b) Telomerase activity in small-cell and non-small-cell lung
cancers. J Natl Canicer Inst 87: 895-902
Hiyama E, Yokoyama T, Tatsumoto N, Hiyama K, Imamura Y, Murakami Y,
Kodama T, Piatyszek MA, Shay JW and Matsuura Y (I995c) Telomerase
activity in gastric cancer. Cancer- Res 55: 3258-3262
Hiyama K, Hirai Y, Kyoizumi S, Akiyama M, Hiyama E, Piatyszek MA, Shay JW,
Ishioka S and Yamakido M (1995d) Activation of telomerase in human
lymphocytes and hematopoietic progenitor cells. J Immunol 155: 3711-3715
Hiyama E, Gollahon L, Kataoka T, Kuroi K, Yokoyama T, Gazdar AF, Hiyama K,
Piatyszek MA and Shay JW (1996) Telomerase activity in human breast
tumours. JNatl Canicer Inst87: 116-122
Hollstein M, Sidranski D, Vogelstein B and Harris C (1991) p53 mutations in human
cancers. Science 253: 49-53
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, HO PLC, Coviello GM,
Wright WE, Weinrich SL and Shay JW (1994) Specific association of human
telomerase activity with immortal cells and cancer. Science 266: 2011-2015
Kinzler KW, Nilbert MC, SU L-K, Vogelstein B, Bryan TM, Levy DB, Smith KJ,
Preisinger AC, Hedge P, McKechnie D, Finniear R, Markham A, Groffen J,
Boguski MS, Altschul SF, Horii A, Ando H, Miyoshi Y, Miki Y, Nishisho I and
Nakamura Y (1991a) Identification of FAP locus genes from chromosome
5q2I. Science 253: 661-665
Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger
AC, Hamilton SR, Hedge P, Markham A, Carlson M, Joslyn G, Groden J,
White R, Miki Y, Miyoshi Y, Nishisho I and Nakamura Y. (19916b)
Identification of a gene located at chromosome 5q2l that is mutated in
colorectal cancers. Science 251: 1366-1370
Langford LA, Piatyszek MA, Xu R, Schold Jr SC and Shay JW (1995) Telomerase
activity in human brain tumours. Lancet 346: 1267-1268
British Journal of Cancer (1997) 75(4), 548-553 C Cancer Research Campaign 1997Telomerase activity in exfoliated colon cancer cells 553
Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, Peltomaki P,
Sistonen P, Aaltonen LA, Nystrom-Lahti M, Guan X-Y, Zhang Ji, Meltzer PS,
YU, J-W, Kao FT, Chen DJ, Cerosaletti KM, Foumier REK, Todd S, Lewis T,
Leach RJ, Naylor S, Weissenbach J, Mecklin J-P, Jarvinen H, Petersen GM,
Hamilton SR, Green J, Jass J, Watson P, Lynch HT, Trent JM, de la Chapelle A,
Kinzler KW and Vogelstein B (1993) Mutations of a muts homolog, in
hereditary nonpolyposis colorectal cancer. Cell 75: 1215-1225
Li Z-H, Salovaara R, Aaltonen LA and Shibata D (1996) Telomerase activity is
commonly detected in hereditary nonpolyposis colorectal cancers. Am J Pathol
148: 1075-1079
Matsumura Y, Hanbury D, Smith J and Tarin D (1994) Non-invasive detection of
malignancy by identification of unusual CD44 gene activity in exfoliated
cancer cells. Br Med J308: 619-624
Morin GB (1989) The human telomere terminal transferase enzyme is a
ribonucleoprotein that synthesizes TTAGGG repeats. Cell 59: 521-529
Rhyu MS (1995) Telomeres, telomerase, and immortality. JNatl Cancer Inst 87:
884-894
Shay JW, Werbin H and Wright WE (1995) You haven't heard the end of it: telomere
loss may link human aging with cancer. Can J Aging 14: 511-524
Smith-Ravin J, England J, Talbot IC and Bodmer W (1995) Detection ofc-Ki-ras
mutations in faecal samples from sporadic colorectal cancer patients. Gult 36:
81-86
Sugino T, Yoshida K, Bolodeoku J, Tahara H, Buley I, Manek S, Wells C, Goodison
S, Ide T, Suzuki T, Tahara E and Tarin D (1996) Telomerase activity in human
breast cancer and benign breast lesions: diagnostic applications in clinical
specimens including fine needle aspirates. IntJ Cancer 69: 301-306
Tahara H, Nakanishi T, Kitamoto M, Nakasho R, Shay JW,Tahara E, Kajiyama G
and Ide T (1995a) Telomerase activity in human liver tissues: comparison
between chronic liver disease and hepatocellular carcinomas Cancer Res 55:
2734-2736
Tahara H, Kuniyasu H, Yasui W, Yokozaki H, Shay JW, Ide T and Tahara E (1995b)
Telomerase activity in preneoploastic and neoplastic gastric and colorectal
lesions. Clin Cancer Res 1: 1245-1251
Yoshida K, Sugino T, Bolodeoku J, Warren BF, Goodison S, Woodman A, Toge T,
Tahara E and Tarin D (1996) Detection ofexfoliated carcinoma cells in colonic
luminal washings by identification ofderanged patterns ofexpression of the
CD44 gene. J Clin Pathol 49: 300-305
C Cancer Research Campaign 1997 British Journal of Cancer (1997) 75(4), 548-553